BPC-157 + TB-500 Blend vs GHK-Cu
BPC-157 + TB-500 Blend (Multi-component research blend) and GHK-Cu (Copper-binding tripeptide) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | BPC-157 + TB-500 Blend | GHK-Cu |
|---|---|---|
| Compound class | Multi-component research blend | Copper-binding tripeptide |
| Research category | Healing & Recovery | Cosmetic & Dermal |
| Length (amino acids) | Not documented | 3 amino acids |
| Molecular weight | Not documented | 340.4 Da |
| Half-life | Not documented | Not documented |
| Origin | This is a research blend combining BPC-157 and TB-500 (a Thymosin Beta-4-related fragment). It is not a naturally occurring substance and exists only as a combination formulated for research contexts. | GHK is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, with levels reported to decline with age. GHK-Cu is its complex with copper(II) ions and is widely used as a cosmetic ingredient. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How BPC-157 + TB-500 Blend works
As a blend, it combines the documented properties of its components: BPC-157, studied in animal models for angiogenesis and growth-factor-related tissue-repair signaling, and TB-500, associated with actin regulation and cell migration in preclinical work. Any combined effect is not independently characterized in controlled human trials.
How GHK-Cu works
GHK has a high affinity for copper(II) and is understood to act partly as a copper-delivery molecule, facilitating copper transport relevant to enzymatic and remodeling processes. In cell and skin research it has been associated with signaling that influences extracellular-matrix remodeling, collagen and glycosaminoglycan synthesis, and antioxidant and gene-expression effects. Much of this work is from in-vitro and skin studies.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
BPC-157 + TB-500 Blend
GHK-Cu
What sets each apart
BPC-157 + TB-500 Blend
This blend pairs a growth-factor/angiogenesis-focused peptide (BPC-157) with an actin-regulating fragment (TB-500), differing from single-peptide or copper-tripeptide products.
GHK-Cu
GHK-Cu is the most established copper tripeptide in cosmetic use, distinguished from AHK-Cu by its sequence and from repair peptides like BPC-157 by its remodeling and copper-delivery focus.
Frequently asked questions
What is the BPC-157 + TB-500 blend?
It is a combined research formulation pairing BPC-157 with TB-500 (thymosin beta-4 related peptide), the two most widely co-studied tissue-repair peptides. Vials are commonly supplied at a 1:1 ratio, for example 5 mg of each (10 mg total) or 10 mg of each (20 mg total). Every dose drawn provides both peptides in the same proportion.
Why are BPC-157 and TB-500 combined?
They are combined because their proposed repair mechanisms are viewed as complementary: BPC-157 is associated with angiogenesis and nitric-oxide signaling, while TB-500 relates to actin regulation and cell migration. In tissue-repair research this pairing is the classic 'systemic + local' repair stack. Any synergy claims remain preclinical and unproven in humans.
How is the blend reconstituted and dosed in research?
For a 10 mg blend (5 mg + 5 mg), adding about 3 mL of bacteriostatic water yields roughly 3.33 mg/mL total (about 1.67 mg/mL of each peptide). Because the two peptides differ in typical dosing scale, protocols usually anchor to the TB-500 milligram schedule while accepting the co-delivered BPC-157 amount. These are reference figures, not dosing guidance.
What is GHK-Cu?
GHK-Cu is a complex of the naturally occurring tripeptide GHK (glycyl-L-histidyl-L-lysine) with a copper(II) ion. The GHK sequence is a subfragment of the alpha-2 chain of type I collagen and is present in human plasma, where its level declines with age. It is studied primarily as a copper-delivery and skin-remodeling signal peptide.
What is GHK-Cu studied for?
In research and cosmetic-formulation literature it is studied for collagen and glycosaminoglycan synthesis in dermal fibroblasts, wound-model remodeling, and antioxidant/gene-modulating activity. It is characterized as a signaling peptide rather than a therapeutic drug, and is not FDA-approved for treating any condition.
Why is a higher GHK-Cu concentration not necessarily better?
Research summaries note a biphasic dose response: GHK-Cu stimulates matrix synthesis at low (picomolar to nanomolar) concentrations, but at higher concentrations it can also upregulate matrix-degrading enzymes. This is why most cosmetic formulation guidance centers on the low end of the topical range rather than maximizing concentration.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.